A method and system for the execution of health management care for allergic rhinitis population

Abstract

The present application belongs to the technical field of medical health management, and particularly relates to a health management and nursing execution method and system for allergic rhinitis population, wherein baseline data of a target patient is acquired; a health management archive is established, so that the target patient wears a sachet at a preset distance from the nostril through an adjustable chest fixing device, a structured log table is used to record daily actual wearing time, medicinal material replacement time and discomfort information, the log table is associated with the health management archive; compliance is evaluated, at least two time nodes set in an intervention period, self-scoring and life quality evaluation are acquired again, compared with baseline data, a change curve is generated and an intervention end evaluation result is obtained; follow-up is carried out at intervals of a preset follow-up period, follow-up symptom evaluation is acquired, and rebound is judged. Thus, the problems in the prior art that intervention effect cannot be quantified and nursing quality is difficult to control are solved.

Description

Technical Field

[0001] This invention belongs to the field of medical and health management technology, and specifically relates to a method and system for implementing health management and nursing care for people with allergic rhinitis. Background Technology

[0002] People with allergic rhinitis face limitations in medication use, and traditional Chinese medicine sachets have become a mainstream non-drug health intervention method due to their gentleness and safety. They are widely used in patients with mild symptoms, pregnant and breastfeeding women, and children, and have a high degree of clinical acceptance.

[0003] Existing technologies only focus on optimizing the herbal formula for sachets, and the intervention method is only vaguely described as wearing them on the body. Patients are instructed verbally to control the wearing distance, duration, and replacement cycle themselves. There are no standardized operating procedures, nor are there any unified quantitative assessment and tracking mechanisms.

[0004] This model lacks baseline data documentation, segmented scale assessment, structured compliance recording, and long-term follow-up comparison processes, making it impossible to quantify intervention effects, verify adherence to usage guidelines, and control nursing quality. Therefore, there is an urgent need for a health management and nursing implementation method and system for people with allergic rhinitis to address the technical deficiencies of lacking standardized usage guidelines and full-cycle quantitative tracking and assessment. Summary of the Invention

[0005] This application provides a method and system for implementing health management and nursing care for people with allergic rhinitis, in order to solve the problems of the inability to quantify intervention effects and the difficulty in controlling nursing quality in the prior art.

[0006] Firstly, the embodiments of this disclosure provide a method for implementing health management care for people with allergic rhinitis, including: Obtain baseline data of the target patients, including self-reported nasal symptoms and quality of life assessments; A health management file is established based on the baseline data. According to the health management file, the target patient wears the sachet at a preset distance from the nostrils using an adjustable chest fixation device. The sachet is worn for no less than a preset duration each day, and the medicinal materials are changed every preset replacement cycle. The sachet is worn continuously for a preset intervention cycle. The actual daily wearing time, the time of medicinal material replacement, and any discomfort information are recorded using a structured log table. The log table is linked to the health management file. Based on the log table, compliance is assessed. At least two time points are set within the intervention period, the self-rating and quality of life assessment are obtained again, compared with the baseline data, a change curve is generated, and the intervention end assessment result is obtained. After the intervention period ends, follow-up visits are conducted at preset intervals to obtain follow-up symptom evaluations. The follow-up symptom evaluations are then compared with the intervention end evaluation results to determine whether a rebound has occurred.

[0007] Secondly, the embodiments of this disclosure provide a health management and care execution system for people with allergic rhinitis, including: The enrollment screening module is used to screen subjects based on diagnostic criteria and establish informed consent records; The health status collection module is used to collect symptom scores and quality of life questionnaire data of subjects at multiple preset time points; The wearing parameter management module is used to record the sachet's wearing position, daily wearing duration, and replacement cycle; The compliance recording module is used for structured recording of nursing care execution logs; The file management module is used to create and update personal health management files; The data analysis module is used to perform trend analysis and nursing quality assessment on node-based health status data.

[0008] Thirdly, embodiments of this disclosure provide a data transmission device, including: processor; Memory, used to store executable instructions; The processor is used to read executable instructions from memory and execute the executable instructions to implement a health management and care execution method for people with allergic rhinitis, as described in the first aspect.

[0009] Fourthly, the embodiments of this disclosure provide a computer-readable storage medium storing a computer program that, when executed by a processor, causes the processor to implement a health management and care execution method for a population with allergic rhinitis according to the first aspect of the embodiments.

[0010] Fifthly, this disclosure provides a computer program product, which includes a computer program that, when executed by a processor, implements a health management and care method for people with allergic rhinitis according to the aforementioned first aspect of the embodiment.

[0011] Therefore, this application includes the following beneficial effects: By first collecting baseline data on patients' nasal symptoms and quality of life to establish a personalized health management file, and using an adjustable chest fixation device to standardize the wearing distance, wearing time, and herbal replacement cycle of the sachet, and relying on a structured log table to completely retain wearing-related information and link it with the file, patient adherence can be accurately monitored. Simultaneously, by repeatedly assessing at multiple time points within the intervention period and comparing baseline data to generate indicator change curves, the intervention effect can be objectively quantified. After the intervention, regular follow-ups are conducted, and symptom evaluation results are compared to identify symptom rebound. This solves the problems of traditional sachet intervention methods, such as lack of standardized implementation guidelines, lack of full-process data tracking, subjective efficacy evaluation, and difficulty in long-term monitoring of recurrence risk. It achieves standardization of the sachet intervention process for allergic rhinitis patients, continuous data management, and objective efficacy evaluation, making it easier for medical staff to dynamically grasp the patient's entire intervention process, adjust health management strategies in a timely manner, and improve the standardization, traceability, and long-term management effectiveness of aromatherapy intervention for allergic rhinitis. Thus, it solves the problems of the inability to quantify intervention effects and the difficulty in controlling nursing quality in existing technologies.

[0012] Additional aspects and advantages of this application will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of this application. Attached Figure Description

[0013] The above and / or additional aspects and advantages of this application will become apparent and readily understood from the following description of the embodiments taken in conjunction with the accompanying drawings, wherein: Figure 1 This is a flowchart illustrating a health management and nursing care method for people with allergic rhinitis, provided according to an embodiment of this disclosure. Figure 2 This is a schematic diagram of a health management and care execution system for people with allergic rhinitis according to an embodiment of this application; Figure 3 This is a schematic diagram of the structure of a data transmission device according to an embodiment of the present disclosure. Detailed Implementation

[0014] Embodiments of this disclosure will now be described in more detail with reference to the accompanying drawings. While some embodiments of this disclosure are shown in the drawings, it should be understood that this disclosure can be implemented in various forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided to provide a more thorough and complete understanding of this disclosure. It should be understood that the accompanying drawings and embodiments of this disclosure are for illustrative purposes only and are not intended to limit the scope of protection of this disclosure.

[0015] It should be understood that the steps described in the method embodiments of this disclosure may be performed in different orders and / or in parallel. Furthermore, the method embodiments may include additional steps and / or omit the steps shown. The scope of this disclosure is not limited in this respect.

[0016] The terminology used herein, including but not limited to, is open-ended. The term "based on" is at least partially based on. The term "one embodiment" refers to at least one embodiment; the term "another embodiment" refers to at least one additional embodiment; the term "some embodiments" refers to at least some embodiments. Relevant definitions for other terms will be given in the description below.

[0017] It should be noted that the concepts of "first," "second," etc., mentioned in this disclosure are used only to distinguish different devices, modules, or units, and are not used to define the order of functions performed by these devices, modules, or units or their interdependencies.

[0018] It should be noted that the one or more modifications mentioned in this disclosure are illustrative rather than restrictive, and those skilled in the art should understand that they should be understood as one or more unless explicitly indicated in the context.

[0019] The names of messages or information exchanged between multiple devices in the embodiments of this disclosure are for illustrative purposes only and are not intended to limit the scope of such messages or information.

[0020] The following describes a method and system for implementing health management and nursing care for people with allergic rhinitis, according to an embodiment of the present disclosure, with reference to the accompanying drawings. To address the difficulty in controlling nursing quality mentioned in the background art, this application provides a method for implementing health management nursing care for people with allergic rhinitis. In this method, a personalized health management file is established by first collecting baseline data on the patient's nasal symptoms and quality of life. An adjustable chest fixation device is used to standardize the wearing distance, duration, and replacement cycle of the sachet. A structured log is used to completely retain relevant wearing information and link it to the file, allowing for precise monitoring of patient adherence. Simultaneously, repeated assessments at multiple time points within the intervention period and comparisons with baseline data generate indicator change curves to objectively quantify the intervention effect. After the intervention, regular follow-ups are conducted, and symptom evaluation results are compared to identify symptom rebound. This method solves the problems of traditional sachet intervention methods, such as lack of standardized implementation guidelines, lack of full-process data tracking, subjective efficacy evaluation, and difficulty in long-term monitoring of recurrence risk. It achieves standardization of the sachet intervention process for people with allergic rhinitis, continuous data management, and objective efficacy evaluation. This allows medical staff to dynamically grasp the patient's entire intervention process, adjust health management strategies in a timely manner, and improve the standardization, traceability, and long-term management effectiveness of aromatherapy nursing intervention for allergic rhinitis. Therefore, it solves the problems of inability to quantify intervention effects and difficulty in controlling nursing quality in existing technologies.

[0021] Specifically, Figure 1 This disclosure provides a method for implementing health management and care for people with allergic rhinitis.

[0022] like Figure 1 As shown, this method for implementing health management and care for people with allergic rhinitis includes the following steps: In step S101, baseline data of the target patient is obtained, including self-reported nasal symptoms and quality of life assessment.

[0023] Baseline data refers to the initial state values ​​obtained by first measuring key indicators before the implementation of a project, experiment, or policy intervention, and is used as the original reference benchmark for subsequent dynamic comparison and effect evaluation.

[0024] Accordingly, baseline data records the nasal symptom scores and quality of life assessments of patients at the initial stage of intervention, forming a unified and objective initial reference benchmark. This benchmark can be used for comparative analysis of indicators at various time points within the intervention period, supporting the generation of symptom change curves, enabling quantitative judgment of intervention effects, and providing original reference for comparative evaluation and identification of symptom rebound during the follow-up stage.

[0025] In this embodiment of the disclosure, the target patients are those diagnosed with allergic rhinitis, excluding those with allergies to sachet ingredients, pregnancy or lactation, severe organ dysfunction, and mental or cognitive impairment, and have signed informed consent forms; the self-score for nasal symptoms is based on the visual analog scale, with nasal congestion, runny nose, nasal itching, and sneezing scored from 0 to 10; the quality of life assessment is based on the nasoconjunctivitis quality of life questionnaire, including dimensions of sleep, behavior, emotion, and activity.

[0026] Among them, the visual analog scale is a subjective assessment tool in which patients mark their pain, anxiety and other experiences on a 100-millimeter straight line marked with pain ranging from no pain to severe pain.

[0027] Correspondingly, the visual analog scale (VAS) scoring method can continuously quantify the four symptoms of nasal congestion, runny nose, nasal itching, and sneezing from 0 to 10 points. It can intuitively distinguish the severity gradient of symptoms, reduce the subjective ambiguity brought about by text-based grading evaluation, facilitate horizontal comparison of data at different time points before and after intervention, support the construction of symptom change curves, and provide standardized quantitative basis for objectively judging the effect of sachet intervention and identifying symptom rebound during follow-up.

[0028] In step S102, a health management file is established based on baseline data. According to the health management file, the target patient wears the sachet at a preset distance from the nostrils using an adjustable chest fixation device. The sachet is worn for no less than a preset duration each day, and the medicine is replaced every preset replacement cycle. The sachet is worn continuously for a preset intervention cycle. The actual daily wearing time, medicine replacement time, and any discomfort information are recorded using a structured log table, and the log table is linked to the health management file.

[0029] The structured log table is a database table that stores unstructured raw log text by breaking it down into standardized columns according to predefined fields. It is designed to support efficient automated parsing, fast retrieval, and metric aggregation analysis.

[0030] Correspondingly, the structured log form records the actual daily wearing time, medication replacement time, and discomfort information in a standardized manner, which enables the standardized retention of data during the intervention process. This facilitates the objective assessment of patient compliance and allows for complete traceability of the entire intervention implementation process. After the log form is linked to the health management file, the correlation between the intervention implementation and symptom improvement can be comprehensively analyzed in conjunction with symptom scores, ensuring that the intervention effect evaluation results are true and reliable.

[0031] In this embodiment, the preset distance is 5-10cm, and the adjustable chest fixation device fixes the sachet to the chest with a pin or a hanging rope so that the sachet is stably kept within this distance range; the preset duration is 6 hours, the preset replacement cycle is 2 weeks, the preset intervention cycle is 4 weeks, and the preset follow-up cycle is 1 month.

[0032] Accordingly, the adjustable chest fixation device can stably maintain the sachet within a 5 to 10 cm range from the nostrils, ensuring stable inhalation of volatile medicinal components while avoiding irritation caused by being too close or reduced efficacy due to being too far away; the effective concentration of the medicinal aroma can be maintained for at least 6 hours a day, the medicinal materials can be replaced every 2 weeks, and the entire intervention cycle of 4 weeks can be completed, ensuring the stable performance of the intervention; a 1-month follow-up period is set after the intervention to facilitate continuous tracking of symptom changes and timely identification of symptom rebound. The entire set of parameters standardizes the intervention plan and reduces the interference of operational differences on the effect evaluation.

[0033] In this embodiment of the disclosure, the structured log table is connected to the hospital information system (HIS) to automatically capture the daily medication records of the target patient and incorporate the medication records into the health management file as a reference for health status.

[0034] Among them, health management records are comprehensive professional information integrations that systematically record an individual's health status, medical history, physical examination indicators, lifestyle and risk factors throughout their entire life cycle, and conduct dynamic tracking and risk assessment, thereby providing a scientific basis for personalized health intervention and disease prevention.

[0035] Accordingly, the health management record integrates patient baseline data, structured log information, symptom evaluations at various time points, and follow-up records, and uniformly collects all intervention-related data to form a complete and continuous personal health data chain. This facilitates cross-time period indicator comparison and analysis, supports compliance assessment and intervention effect determination, and provides complete data support for the standardized implementation of allergic rhinitis health management and nursing work throughout the entire process.

[0036] In step S103, compliance is assessed based on the log table. At least two time points set within the intervention period, self-ratings and quality of life assessments are obtained again, compared with baseline data, and change curves are generated to obtain the intervention end assessment results.

[0037] Compliance refers to the degree to which a patient's behavior aligns with clinical medical advice or health recommendations during the process of receiving healthcare services.

[0038] Accordingly, conducting compliance assessments based on log sheets can objectively grasp the actual implementation status of patients, distinguish whether the difference in intervention effect comes from the efficacy of the program itself or the patient's failure to wear it correctly, eliminate data interference caused by insufficient compliance, improve the credibility of the symptom improvement results, and provide targeted health guidance based on the compliance assessment results, ensuring the smooth implementation of the allergic rhinitis nursing intervention program.

[0039] In this embodiment of the disclosure, at least two time points include week 2 and week 4; at the time point of week 2, tolerance information of the target patients is also collected, including the degree of acceptance of the odor, whether there is a pungent sensation and whether there is skin itching.

[0040] Among them, tolerability information refers to pharmacological data, clinical indicators, and related medication guidelines regarding the progressive decrease in the body's responsiveness after repeated use of a certain drug or exogenous substance, requiring increased dosage to maintain the original pharmacological effect.

[0041] Accordingly, collecting tolerance information can promptly grasp the patient's acceptance of the sachet's odor, the degree of irritation and skin itching, identify adverse reactions as early as possible, avoid adverse experiences caused by continuous wearing, and incorporate tolerance into the overall assessment system to eliminate the interference of adverse reactions on symptom scores, ensure the safe conduct of intervention trials, and help objectively distinguish whether symptom changes are due to allergic rhinitis itself or sachet stimulation.

[0042] In this embodiment of the disclosure, the method further includes: obtaining pollen concentration data of the area where the target patient is located, and using the pollen concentration data as a control variable when comparing self-scores and generating change curves, so as to reduce the interference of pollen concentration fluctuations on symptom assessment.

[0043] Accordingly, by introducing pollen concentration data from the target patient's region as a control variable, the influence of fluctuations in external pollen concentration on nasal symptom scores can be eliminated, the assessment bias caused by environmental factors can be reduced, the symptom changes caused by environmental triggers and sachet intervention can be distinguished, the symptom change curve can be made to truly reflect the effect of sachet intervention, the conclusions can be effectively avoided by environmental confounding factors, and the objectivity and accuracy of the evaluation of the intervention effect of allergic rhinitis can be improved.

[0044] In step S104, after the intervention period ends, follow-up visits are conducted at preset intervals to obtain follow-up symptom evaluations. The follow-up symptom evaluations are compared with the intervention end evaluation results to determine whether a rebound has occurred.

[0045] Among them, follow-up symptom evaluation refers to a standardized, quantitative, or qualitative systematic assessment of the severity, frequency, nature, and impact on daily living functions of patients' subjective discomfort symptoms at predetermined follow-up time points during clinical research or healthcare.

[0046] Accordingly, conducting follow-up symptom evaluation can capture the dynamic changes in patients' nasal symptoms after the intervention period ends. By comparing the follow-up symptom evaluation results with the intervention end evaluation results, it is possible to accurately determine whether allergic rhinitis-related symptoms have rebounded, continuously test the long-term effectiveness of the sachet intervention, improve the whole-cycle evaluation chain, and avoid one-sided evaluation conclusions caused by relying solely on data from the intervention stage.

[0047] The following will illustrate a method for implementing health management and nursing care for people with allergic rhinitis through a specific embodiment, including: In the early stages of the practice, subject stratification screening was completed according to regulations, with the inclusion age range set at 18 to 65 years old. All enrolled subjects were diagnosed with typical symptoms of allergic rhinitis. Before enrollment, a unified exclusion check was conducted, which included four categories of conditions: history of allergy to the Chinese herbal ingredients in the sachet, pregnancy, breastfeeding, severe multiple organ dysfunction, and cognitive impairment. Subjects with any of these conditions were directly excluded. All retained subjects completed the written informed consent process to avoid ethical risks and ensure that subjects were fully aware of the entire nursing procedure, assessment frequency, wearing requirements, data collection purpose, and long-term follow-up arrangements, confirming their willingness to participate and their ability to fully cooperate with the assessment, wear the sachet on time, and complete the structured log form correctly. After personnel screening was completed, baseline data acquisition was initiated simultaneously. The baseline data consisted of two core modules. The first module was a self-assessment of nasal symptoms, using a unified visual analog scale (VAS) method. Four core nasal discomforts—congestion, runny nose, itchy nose, and sneezing—were assessed from 0 to 10 points, with 0 representing no related discomfort and 10 representing symptoms reaching the tolerance limit. Subjects completed the assessment independently, with nursing staff providing only guidance and not interfering with subjective scores. The second module was a quality of life assessment, using a unified nasal-conjunctivitis quality of life questionnaire covering four core dimensions: sleep status, limitations in daily activities, emotional state, and limitations in outdoor activities. All raw scores were simultaneously entered into the information system. Based on all collected baseline data, a unique health management file was generated for each subject. This file served as the data storage medium for the entire lifecycle. All subsequent wear records, assessment scores at different stages, medication information, pollen-related data, and follow-up feedback were uniformly archived into the corresponding file entries, achieving centralized management of individual data throughout the entire process.

[0048] After the baseline data is established, the standardized wearing and implementation phase begins. The wearing medium is a breathable cotton sachet filled with a mixture of angelica, mint, magnolia flower, fried cocklebur, and artemisia leaf powder. An adjustable chest fixation device is used to constrain the wearing position. The fixation device has two structural forms: an adjustable length hanging rope and a detachable pin. Subjects can freely choose the fixation accessories according to their daily clothing habits. Nursing staff uniformly assist in adjusting the distance between the sachet and the nostrils, strictly controlling the range to be maintained between 5 cm and 10 cm. The adjustment structure of the fixation device can lock the position of the sachet, preventing the sachet from shifting too far from the nostrils or being too close to the nasal cavity during activities. This eliminates the defects of the traditional portable sachet mode, such as unrestrained sachet position and inability of effective volatile components to stably reach the nasal cavity. The minimum wearing time is set at no less than 6 hours per day. Nursing staff provide standardized education to subjects, clarifying that 6 hours is the basic threshold for effective intervention. Wearing time below this value will directly affect the intervention effect. A fixed replacement cycle for the medicinal materials is set at two weeks. Regardless of the subject's subjective perception of the medicinal smell, the powder core is replaced with a brand new one upon reaching the replacement cycle. This prevents the problem of relying on the sense of smell to subjectively judge the replacement time, which could lead to the complete loss of volatile oils and ineffective intervention. The overall standardized wearing intervention cycle is fixed at four weeks. Within four weeks, the daily wearing operation is carried out in accordance with the three hard parameters of distance, duration, and replacement cycle. A standardized structured log is used to record compliance throughout the entire wearing cycle. The log entries include the actual cumulative wearing time each day, the precise date of replacement of the medicinal materials in the sachet, and various discomfort feedback information such as skin itching, nasal congestion, and odor intolerance during wearing. After the subject completes the information entry each day, the system automatically synchronizes the daily log content to the individual's personalized health management file, forming a traceable record chain that corresponds one-to-one with wearing behavior and health data.

[0049] Based on the daily wear data continuously recorded in the log, nursing staff conducted stratified compliance assessments of subjects in batches, using 6 hours per day as the baseline for achieving compliance. The percentage of days that met the standard was statistically analyzed within the period. One-on-one health education was provided to subjects who failed to meet the standard for several consecutive days, correcting bad habits such as casual wearing, intermittent wearing, and shortening the wearing time. Simultaneously, two fixed assessment time nodes were set within the four-week intervention period, corresponding to the second week and the fourth week after the intervention. At both nodes, the same set of visual analog scales and nasal conjunctivitis quality of life questionnaires from the baseline stage were used again to re-collect subjects' self-ratings of nasal symptoms and quality of life evaluation scores. The system automatically retrieved the original baseline data in the file to complete the comparison with the subjects' values ​​before and after. Based on multiple sets of continuously collected scores, a symptom improvement curve over time was automatically generated. The curve simultaneously marked the statistical difference and significance results corresponding to each set of scores. Finally, a standardized evaluation result at the end of the intervention was generated, which intuitively presented the overall improvement of subjects' symptoms and quality of life within the four-week complete intervention period. The mid-term assessment during the second week of intervention included a tolerance information collection component. Based on the completion of scale scoring, a structured simplified questionnaire was used to record three types of tolerance-related content: the subject's subjective acceptance of the volatile odor of the sachet, whether they experienced nasal irritation or stuffiness during wearing, and whether they experienced allergic reactions such as itching or redness on the skin in contact with the sachet on their chest. Tolerance information was separately archived in the health management file for subsequent optimization of the sachet powder ratio, adjustment of the focus of wearing education, and improvement of long-term wearing compliance.

[0050] After the completion of the four-week standardized intervention cycle, a fixed follow-up cycle of one month was set. At the follow-up point, the subjects were contacted again to complete the follow-up symptom evaluation. The evaluation scale used the same standard as the baseline, mid-term and endpoint assessments. The system retrieved the intervention end evaluation results generated when the four-week intervention was completed and compared them item by item with the new score data collected during the follow-up. The change in score difference was used to determine whether the subject's nasal symptoms rebounded. The long-term symptom fluctuation pattern was fully recorded, and the long-term tracking data dimension of the health management file was improved, so as to achieve dual monitoring of short-term intervention effect and long-term maintenance status. This implementation process is supported by an information management system. The system has a built-in structured log form digital entry port, which connects to the hospital's information system. The connection channel can automatically capture the records of anti-allergy nasal spray hormone medications used by subjects during their daily outpatient and inpatient periods. All captured medication information is automatically categorized into personal health management files, serving as an auxiliary reference indicator for the subject's health status throughout the entire period. When analyzing changes in scale scores, nursing staff can simultaneously combine the medication situation during the same period to distinguish the source of symptom improvement, avoiding interference from oral or topical nasal medications on the evaluation of the health management effect of sachet, and making the results of multi-node score comparisons more consistent with the true effect of sachet as a single intervention.

[0051] The system synchronously connects to the pollen concentration monitoring data application interface, which can automatically retrieve real-time pollen concentration values ​​within a 50-kilometer radius of the subject's residential area. These values ​​are updated to the corresponding health management records along with daily log entries. Throughout the process of comparing scale scores at baseline, second week, fourth week, and long-term follow-up, and generating symptom change curves, pollen concentration values ​​at the corresponding collection time period are included as data control variables. When interpreting the data, nursing staff can simultaneously match the fluctuations in pollen levels during the same period, distinguishing between symptom aggravation caused by increased pollen concentration and score rebound caused by insufficient adherence to wearing the sachet. This significantly reduces the interference of environmental pollen fluctuations on the quantitative assessment results of symptoms, and solves the assessment bias problem of traditional sachet care, which cannot distinguish between environmental triggers and intervention implementation defects. This makes the statistical analysis conclusions of multi-node score differences more reliable.

[0052] The baseline overall visual analog scale (VAS) score of the 128 participants was 4.49, with a standard deviation of 2.074 and a standard error of 0.184. The overall quality of life assessment score for nasal conjunctivitis was 2.52, with a standard deviation of 1.106 and a standard error of 0.098. The baseline data indicate that all participants had moderate allergic rhinitis symptoms, and their daily life dimensions, including sleep, activity, and mood, were significantly negatively affected. This data suggests that the participants have intervention value for standardized sachet health management. By the midpoint of the second week of intervention, 127 subjects had completed effective assessments. The mean visual analog scale (VAS) score had decreased to 4.04, with a difference of 0.45 from the baseline. A paired-samples t-test yielded a t-value of 2.453 and a two-sided significance level of 0.016, indicating a statistically significant difference. The mean quality of life assessment for nasal conjunctivitis had decreased to 2.17, with a difference of 0.35 from the baseline. A t-value of 3.887 and a two-sided significance level of less than 0.001 indicated a more significant difference in quality of life improvement. Tolerance data were simultaneously assessed in the second week. Only a few subjects reported mild odor intolerance, with no severe adverse reactions such as severe skin allergies or persistent nasal coughing. After providing education and correction to subjects who consistently failed to meet the recommended wearing time, the percentage of subjects who met the adherence requirements in the subsequent two weeks significantly increased.

[0053] At the four-week endpoint assessment stage of the intervention, 124 participants successfully completed data collection. Four participants dropped out, all due to their inability to complete the sub-scale assessments on time. There were no cases of withdrawal due to serious adverse reactions related to wearing the device. The mean visual analog scale score decreased to 3.54, with a difference of 0.93 from the baseline mean. The paired-samples t-test t-value was 4.196, and the two-sided significance value was less than 0.001. The mean score for quality of life assessment of nasal conjunctivitis decreased to 1.95, with a difference of 0.57 from the baseline mean. The t-value was 4.593, and the two-sided significance value was less than 0.001. The 95-point confidence intervals for both core score indicators did not cross zero, confirming that the symptom and quality of life improvements brought about by the four-week standardized wearing intervention were not due to random data fluctuations and had a stable and repeatable health improvement effect. Correlation analysis showed that the correlation coefficient between the visual analog scale (VAS) score after four weeks of intervention and the baseline VAS score was 0.333, with a significance level less than 0.001. The correlation coefficient before and after the assessment of quality of life for nasal conjunctivitis was 0.334, also with a significance level less than 0.001. This indicates that regardless of the severity of symptoms at the initial stage of enrollment, the standardized wearing procedure consistently provides health improvements and does not have the limitation of being effective only for subjects with severe symptoms. Long-term follow-up data showed that the scores after one month of follow-up did not show a significant upward trend compared to the four-week intervention endpoint, and the proportion of symptom rebound cases was extremely low. This confirms that the health improvements brought about by this standardized sachet health management are sustainable and not a short-term relief effect that quickly regresses after discontinuation of wearing.

[0054] In summary, this invention ensures the safety, compliance, and baseline balance of the trial through rigorous subject screening, ethical review, and risk exclusion. It standardizes core parameters such as the wearing distance and duration of the sachet, and the replacement cycle of medicinal materials, and combines this with structured log recording, multi-node assessment, and targeted compliance education to effectively avoid the problems of arbitrary operation and unstable effects in traditional sachet interventions, reducing trial bias. By integrating medication records and regional pollen concentration data through an information system, it effectively eliminates interference from environmental and drug-related confounding factors, improving the accuracy of efficacy evaluation and statistical analysis, and constructing a quantifiable and traceable end-to-end management system. Clinical results confirm that this standardized intervention program can effectively improve patients' nasal symptoms and enhance their quality of life. Patients tolerate it well, and the long-term efficacy is stable. It overcomes the shortcomings of insufficient standardization and weak data support in traditional Chinese medicine external treatments, providing a replicable and standardized practice paradigm for characteristic TCM nursing care of allergic rhinitis, and also providing reliable practical and data support for subsequent program optimization and related research.

[0055] Figure 2 This is a schematic diagram of the structure of a health management and nursing execution system for people with allergic rhinitis according to an embodiment of this disclosure.

[0056] like Figure 2As shown, the health management and nursing execution system 10 for people with allergic rhinitis includes: an enrollment screening module 100, a health status collection module 200, a wearing parameter management module 300, a compliance recording module 400, a file management module 500, and a data analysis module 600.

[0057] The system includes: a screening module 100 for selecting subjects based on diagnostic criteria and establishing informed consent records; a health status collection module 200 for collecting symptom scores and quality of life questionnaire data from subjects at multiple preset time points; a wearing parameter management module 300 for recording the sachet wearing position, daily wearing duration, and replacement cycle; a compliance record module 400 for structured recording of nursing execution logs; a file management module 500 for establishing and updating personal health management files; and a data analysis module 600 for performing trend analysis and nursing quality assessment on the node-based health status data.

[0058] According to the embodiments of this disclosure, a health management and nursing execution system for people with allergic rhinitis is proposed. This system utilizes an enrollment screening module to achieve standardized subject inclusion and informed consent process documentation; a health status collection module to collect standardized data on symptom scores and quality of life at multiple time points; a sachet wearing management module to record relevant information; a compliance recording module to form a structured nursing execution log; a file management module to construct dynamically updated personal health management files; and finally, a data analysis module to conduct trend analysis and quantitative assessment of nursing quality based on the node-based health data. This entire system establishes a complete data link for sachet nursing care for people with allergic rhinitis, addressing the pain points of traditional nursing models such as non-standard subject selection, fragmented health data, difficulty in tracking sachet usage, lack of quantitative recording of nursing compliance, and inability to objectively assess intervention effects. It achieves standardization, data traceability, and quantifiable efficacy throughout the sachet nursing care process for allergic rhinitis, facilitating medical staff to accurately grasp changes in the health of subjects and the implementation of nursing care, continuously optimizing nursing plans, and improving the standardization and effectiveness of health management for people with allergic rhinitis.

[0059] The following will illustrate a health management and care implementation system for people with allergic rhinitis through a specific embodiment, including: This health management and nursing execution system relies on six functional modules to complete the digital management and control of health management for people with allergic rhinitis using sachets. The entire process only involves non-therapeutic health monitoring and nursing quality control. The system has been validated based on a sample of 128 subjects. All data is automatically calculated and stored by the system, eliminating the need for manual statistics.

[0060] The system's enrollment screening module incorporates standardized admission criteria, strictly matching the corresponding treatment guidelines. It limits the age range of subjects to 18 to 65 years old and automatically excludes individuals with allergies to the herbs used in the sachet, those with severe organ damage, cognitive impairment, or who are pregnant or breastfeeding. The electronic informed consent records of the selected subjects are directly stored in the system database, which is simultaneously connected to the hospital's information system to automatically synchronize basic information on medical visits and medications, significantly reducing the workload of manual data entry for nursing staff. In this application, a total of 128 subjects successfully completed enrollment registration, and the screening process was free of standard errors and information omissions.

[0061] The health status collection module has four fixed data collection nodes: baseline, week 2 of intervention, week 4 of intervention, and 30-day follow-up after the end of intervention. It includes a built-in visual analog scale (VAS) and a standard rhinitis quality of life questionnaire, and automatically intercepts abnormal data entries. The mean baseline VAS score for all subjects was 4.49, and the mean quality of life score was 2.52. At week 2 of intervention, the mean VAS score for 127 valid samples was 4.04, and the mean quality of life score was 2.17. At week 4 of intervention, the mean VAS score for 124 valid samples was 3.54, and the mean quality of life score was 1.95. The system automatically performed paired statistical tests, and the differences in scores at each stage were statistically significant. It also automatically generated trend charts of score changes, visually presenting the continuous improvement of symptoms.

[0062] The wearing parameter management module standardizes three parameters: a wearing distance of 5 to 10 cm, a daily wearing time of no less than 6 hours, and the replacement of medicinal materials every 2 weeks. It records the wearing device, daily wearing time, and medicinal material replacement time in real time. The system automatically identifies records of non-compliant wearing and sends nursing reminders. Over the entire application, tens of thousands of wearing records have been accumulated. After system intervention, the daily compliance rate of subjects increased from 65% to 92.7%, and the number of cases of overdue sachet replacement was significantly reduced, achieving full-process digital quality control of the wearing operation.

[0063] The compliance recording module establishes a structured electronic nursing log, synchronously recording wearing time and medication replacement records. Nursing staff only need to supplement and enter information on adverse reactions such as skin discomfort and odor intolerance. The module is linked to a meteorological pollen data interface to automatically capture pollen concentration within 50km of the subject, binding and storing daily environmental data with the subject's symptom scores and wearing records, accumulating more than 20,000 related data points. This allows nursing staff to distinguish the different effects of pollen fluctuations and sachet wearing on symptoms.

[0064] The file management module automatically collects all data from the other five modules, generating an independent encrypted electronic file for each participant. This file comprehensively includes screening records, multi-node scales, wearing logs, and pollen-related data. This application generated 124 complete files, with four files marked and archived due to participants dropping them midway through the process, resulting in an overall dropout rate of only 3.1%. The files support multi-dimensional and rapid retrieval, making the efficiency of review and retrieval far superior to traditional paper files.

[0065] The data analysis module automatically performs batch sample statistical calculations, outputting the difference between the mean and standard deviation of each group's scores, the test value, and the 95% confidence interval. None of the four confidence intervals crossed zero, corroborating the statistical significance of symptom improvement. The system calculated the correlation coefficients between the two scores and baseline at week 4 of the intervention to be 0.333 and 0.334, respectively, with corresponding significance values ​​both less than 0.001, indicating that this management model is effective for individuals with varying degrees of symptom severity. The module automatically generates nursing quality control reports, summarizing indicators such as the inclusion rate, compliance rate, and adverse reaction rate. All quality control conclusions are based on objective quantitative data, eliminating subjective judgment bias.

[0066] In summary, this invention utilizes six functional modules to achieve digitalized and standardized non-therapeutic monitoring and quality control management of the entire process of sachet health care. It can accurately screen subjects, automatically synchronize in-hospital medical information, reduce manual data entry errors and workload, intelligently collect and analyze health data through standardized nodes and professional scales, intuitively present the intervention and improvement effects, solidify the standards for sachet wearing and dressing changes and intelligently warn of non-standard operations, improve subject care compliance, accurately identify symptom influencing factors by combining environmental data, automatically collect various data to form encrypted electronic files, improve review and retrieval efficiency, and output objective quality control results based on intelligent data analysis, avoiding human judgment bias, effectively standardizing the nursing process and improving the refinement and scientific level of rhinitis sachet health management.

[0067] like Figure 3 As shown, the data transmission device may include a processor 301 and a memory 302 storing computer program instructions.

[0068] In some specific embodiments, the processor 301 described above may include a central processing unit (CPU), or an application-specific integrated circuit (ASIC), or one or more integrated circuits that can be configured to implement the embodiments of this application.

[0069] Memory 302 may include a mass storage device for information or instructions. For example, and not limitingly, memory 302 may include a hard disk drive (HDD), floppy disk drive, flash memory, optical disk, magneto-optical disk, magnetic tape, or Universal Serial Bus (USB) drive, or a combination of two or more of these. Where appropriate, memory 302 may include removable or non-removable (or fixed) media. Where appropriate, memory 302 may be internal or external to the integrated gateway device. In a particular embodiment, memory 302 is a non-volatile solid-state memory. In a particular embodiment, memory 302 includes read-only memory (ROM). Where appropriate, the ROM may be a mask-programmed ROM, a programmable ROM (PROM), an erasable PROM (EPROM), an electrically erasable programmable PROM (EEPROM), an electrically alterable ROM (EAROM), or flash memory, or a combination of two or more of these.

[0070] The processor 301 reads and executes computer program instructions stored in the memory 302 to perform the steps of a health management and care method for people with allergic rhinitis provided in this embodiment of the present disclosure.

[0071] In one example, the data transmission device may further include a transceiver 303 and a bus 304. Wherein, as... Figure 3 As shown, the processor 301, memory 302 and transceiver 303 are connected via bus 304 and communicate with each other.

[0072] Bus 304 may include hardware, software, or both. For example, and not limitingly, the bus may include an Accelerated Graphics Port (AGP) or other graphics bus, an Extended Industry Standard Architecture (EISA) bus, a Front Side Bus (FSB), a Hyper Transport (HT) interconnect, an Industrial Standard Architecture (ISA) bus, an Infinite Bandwidth Interconnect, a Low Pin Count (LPC) bus, a memory bus, a MicroChannel Architecture (MCA) bus, a Peripheral Component Interconnect (PCI) bus, a PCI-Express (PCI-X) bus, a Serial Advanced Technology Attachment (SATA) bus, a Video Electronics Standards Association Local Bus (VLB) bus, or other suitable buses, or a combination of two or more of these. Where appropriate, bus 304 may include one or more buses. Although specific buses are described and illustrated in the embodiments of this application, this application considers any suitable bus or interconnection.

[0073] This disclosure also provides a computer-readable storage medium that can store a computer program. When the computer program is executed by a processor, the processor enables the processor to implement a health management and care method for people with allergic rhinitis provided in this disclosure.

[0074] The aforementioned storage medium may, for example, include a memory 302 containing computer program instructions, which can be executed by the processor 301 of the battery internal resistance detection device to complete the battery internal resistance detection method provided in this embodiment. In some embodiments, the storage medium may be a non-transitory computer-readable storage medium, such as a ROM, random access memory (RAM), compact disc ROM (CD-ROM), magnetic tape, floppy disk, and optical data storage device.

[0075] This disclosure also provides a computer program product, which includes a computer program that, when executed by a processor, implements a health management and care method for people with allergic rhinitis provided in this disclosure.

[0076] Furthermore, the foregoing explanations and descriptions of the method and apparatus embodiments also apply to the devices, computer-readable storage media, computer program products, and computer programs described above, and will not be repeated here.

[0077] Furthermore, in this document, relational terms such as "first" and "second" are used merely to distinguish one entity or operation from another, without necessarily requiring or implying any such actual relationship or order between these entities or operations. Moreover, the term "include" is intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus.

[0078] The above description is merely a specific embodiment of this disclosure, enabling those skilled in the art to understand or implement it. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of this disclosure. Therefore, this disclosure is not to be limited to the embodiments described herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

[0079] All embodiments disclosed herein can be executed individually or in combination with other embodiments, and are all considered to be within the scope of protection claimed by this disclosure.

Claims

1. A method for implementing health management and nursing care for people with allergic rhinitis, characterized in that, include: Obtain baseline data of the target patients, including self-reported nasal symptoms and quality of life assessments; A health management file is established based on the baseline data. According to the health management file, the target patient wears the sachet at a preset distance from the nostrils using an adjustable chest fixation device. The sachet is worn for no less than a preset duration each day, and the medicinal materials are changed every preset replacement cycle. The sachet is worn continuously for a preset intervention cycle. The actual daily wearing time, the time of medicinal material replacement, and any discomfort information are recorded using a structured log table. The log table is linked to the health management file. Based on the log table, compliance is assessed. At least two time points are set within the intervention period, the self-rating and quality of life assessment are obtained again, compared with the baseline data, a change curve is generated, and the intervention end assessment result is obtained. After the intervention period ends, follow-up visits are conducted at preset intervals to obtain follow-up symptom evaluations. The follow-up symptom evaluations are then compared with the intervention end evaluation results to determine whether a rebound has occurred.

2. The method for implementing health management and nursing care for people with allergic rhinitis according to claim 1, characterized in that, The preset distance is 5-10cm, and the adjustable chest fixation device fixes the sachet to the chest with a pin or hanging rope so that the sachet is stably kept within this distance range; the preset duration is 6 hours, the preset replacement cycle is 2 weeks, the preset intervention cycle is 4 weeks, and the preset follow-up cycle is 1 month.

3. The method for implementing health management and nursing care for people with allergic rhinitis according to claim 1, characterized in that, The at least two time points include week 2 and week 4; at the time point of week 2, the tolerance information of the target patients is also collected, including the degree of acceptance of odor, whether there is a pungent feeling and whether there is skin itching.

4. The method for implementing health management and nursing care for people with allergic rhinitis according to claim 1, characterized in that, The structured log table is integrated with the hospital information system (HIS) to automatically capture the target patient's daily medication records, and these records are incorporated into the health management file as a reference for health status.

5. A method for implementing health management and nursing care for people with allergic rhinitis according to claim 1, characterized in that, Also includes: By acquiring pollen concentration data of the target patient's area and using this data as a control variable when comparing the self-score and generating a change curve, the interference of pollen concentration fluctuations on symptom assessment can be reduced.

6. A method for implementing health management and nursing care for people with allergic rhinitis according to claim 1, characterized in that, The target patients were those diagnosed with allergic rhinitis, excluding those with allergies to sachet ingredients, pregnancy or lactation, severe organ dysfunction, and mental or cognitive impairment, and all of whom had signed informed consent forms. The self-assessment of nasal symptoms was conducted using the visual analog scale, with nasal congestion, runny nose, nasal itching, and sneezing scored from 0 to 10. The quality of life assessment was conducted using the Nasal Conjunctivitis Quality of Life Questionnaire, which included dimensions of sleep, behavior, emotion, and activity.

7. A health management and nursing care execution system for people with allergic rhinitis, characterized in that, include: The enrollment screening module is used to screen subjects based on diagnostic criteria and establish informed consent records; The health status collection module is used to collect symptom scores and quality of life questionnaire data of subjects at multiple preset time points; The wearing parameter management module is used to record the sachet's wearing position, daily wearing duration, and replacement cycle; The compliance recording module is used for structured recording of nursing care execution logs; The file management module is used to create and update personal health management files; The data analysis module is used to perform trend analysis and nursing quality assessment on node-based health status data.

8. A data transmission device, characterized in that, include: processor; Memory, used to store executable instructions; The processor is configured to read the executable instructions from the memory and execute the executable instructions to implement the health management and care execution method for people with allergic rhinitis according to any one of claims 1 to 6.

9. A computer-readable storage medium, characterized in that, The storage medium stores a computer program that, when executed by a processor, causes the processor to implement a health management and care method for people with allergic rhinitis according to any one of claims 1 to 6.

10. A computer program product, characterized in that, The computer program product includes a computer program that, when executed by a processor, implements a health management and care method for people with allergic rhinitis as described in any one of claims 1 to 6.

Images